China’s Great Leap into Biotech
January 19, 2018
(Bloomberg) – So far, CAR-T has shown extraordinary results. More than 60 percent of children treated with Kymriah were cured, while the rate of full remission for patients treated with Yescarta was more than half. The big problem is price. Kymriah costs $475,000 for a single treatment; Yescarta goes for $373,000. Now China reckons it can do this better and cheaper. There are currently 153 CAR-T studies in the nation, just behind 186 in the U.S., according to Bernstein Research’s Laura Nelson Carney.